Inventor · disambiguated record
Björn Frendéus
Also filed as: FRENDEUS BJOERN · FRENDEUS BJORN · FRENDEUS BJÖRN · FRENDÉUS BJORN
14 granted patents·19 pending applications·31 citations·filing 2003–2025
88Inventor score
Top patents by PatentIndex Score
33 records- 0190US7943744B2ICAM-1 binding antibodiesBIOINVENT INT AB·Filed 2006·Granted May 17, 2011·15 cites·19 claims
- 0285US11623005B2Combined use of FcγRIIb (CD32B) and CD20 specific antibodiesUNIV SOUTHAMPTON·Filed 2019·Granted Apr 11, 2023·3 cites·5 claims
- 0376US8758749B2Biological materials and uses thereofFRENDÉUS BJORN·Filed 2011·Granted Jun 24, 2014·4 cites·25 claims
- 0475US10351970B2Method for screening anti-ligand libraries for identifying anti-ligands specific for differentially and infrequently expressed ligandsBIOINVENT INT AB·Filed 2016·Granted Jul 16, 2019·1 cites·21 claims
- 0573US11447549B2Combination of a Treg depleting anti-4-1BB antibody and anti-PD1 antibodyBIOINVENT INT AB·Filed 2018·Granted Sep 20, 2022·1 cites·14 claims
- 0671US2025066492A1Agonistic anti tnfr2 antibody moleculesBIOINVENT INT AB·Filed 2024·Application pending·0 cites
- 0770US2021346498A1Combined use of fc gamma riib (cd32b) and cd20 specific antibodiesUNIV SOUTHAMPTON·Filed 2021·Application pending·0 cites
- 0869US2025388690A1Novel antagonistic anti-tnfr2 antibodiesBIOINVENT INT AB·Filed 2025·Application pending·0 cites
- 0968US8592347B2Method for screening anti-ligand libraries for identifying anti-ligands specific for differentially and infrequently expressed ligandsFRENDEUS BJOERN·Filed 2003·Granted Nov 26, 2013·5 cites·22 claims
- 1065US10525129B2Combined use of Fc gamma RIIb (CD32B) and CD20-specific antibodiesCRAGG MARK·Filed 2011·Granted Jan 7, 2020·2 cites·32 claims
- 1164US12291569B2Antibodies and nucleotide sequences, and uses thereofBIOINVENT INT AB·Filed 2019·Granted May 6, 2025·0 cites·8 claims
- 1264US2025257135A1Novel antibodies and nucleotide sequences, and uses thereofBIOINVENT INT AB·Filed 2025·Application pending·0 cites
- 1363US12139547B2Agonistic anti TNFR2 antibody moleculesBIOINVENT INT AB·Filed 2019·Granted Nov 12, 2024·0 cites·29 claims
- 1463US2023058227A1Novel antibodies and combined use of a treg depleting antibody and an immunostimulatory antibodyBIOINVENT INT AB·Filed 2022·Application pending·0 cites
- 1562US12441805B2Antagonistic anti-TNFR2 antibodiesBIOINVENT INT AB·Filed 2019·Granted Oct 14, 2025·0 cites·29 claims
- 1661US2014200152A1Method for screening anti-ligand libraries for identifying anti-ligands specific for differentially and infrequently expressed ligandsBIOINVENT INT AB·Filed 2013·Application pending·0 cites
- 1760US9803013B2Biological materials and uses thereofBIOINVENT INT AB·Filed 2014·Granted Oct 31, 2017·0 cites·15 claims
- 1858US2024374719A1Novel combinations of antibodies and uses thereofBIOINVENT INT AB·Filed 2022·Application pending·0 cites
- 1958US2025326849A1COMBINATION OF A FcyRIIB- AND A TUMOR ANTIBODY FOR USE IN THE TREATMENT OF AN FcyRIIB-NEGATIVE CANCERUNIV SOUTHAMPTON·Filed 2023·Application pending·0 cites
- 2057US2024301070A1Improving antibody tolerability associated with intravenous administrationBIOINVENT INT AB·Filed 2021·Application pending·0 cites
- 2157US2023322933A1Model for prediction of tolerability issues in connection with intravenous administration of therapeutic antibodiesBIOINVENT INT AB·Filed 2021·Application pending·0 cites
- 2254US2015352207A1Use of antibodies against icam-1 in combination with an anti cancer drug in the treatment of patientsBIOINVENT INT AB·Filed 2014·Application pending·0 cites
- 2354US2023070339A1Lilrb3 antibody molecules and uses thereofUNIV SOUTHAMPTON·Filed 2021·Application pending·0 cites
- 2453US2024092912A1Novel combinations of antibodies and uses thereofBIOINVENT INT AB·Filed 2022·Application pending·0 cites
- 2551US2018221482A1Use of antibodies against icam-1 in combination with an anti cancer drug in the treatment of patientsBIOINVENT INT AB·Filed 2017·Application pending·0 cites
- 2647US2016280788A1Use of antibodies against icam-1 in the treatment of patients with relapsed cancerBIOINVENT INT AB·Filed 2016·Application pending·0 cites
- 2746US12344673B2Medicaments, uses and methodsBIOINVENT INT AB·Filed 2015·Granted Jul 1, 2025·0 cites·14 claims
- 2846US2022259309A1Antibody combinations for treatment of cancer in specific patientsBIOINVENT INT AB·Filed 2020·Application pending·0 cites
- 2944US12371498B2Combination and use of antibodiesBIOINVENT INT AB·Filed 2019·Granted Jul 29, 2025·0 cites·16 claims
- 3041US2013189260A1Use of antibodies against icam-1 in the treatment of patients with relapsed cancerHANSSON MARKUS·Filed 2011·Application pending·0 cites
- 3134US2011256134A1Methods of treatment using anti-oxidized ldl antibodiesBUNTING STUART·Filed 2010·Application pending·0 cites
- 3232US2012087916A1Anti-icam-1 antibody, uses and methodsFRENDEUS BJORN·Filed 2010·Application pending·0 cites
- 3331US10191049B2Screening methods and uses thereofBIOINVENT INT AB·Filed 2012·Granted Jan 29, 2019·0 cites·21 claims
Join the waitlist — get patent alerts
Get an alert when Björn Frendéus files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →